Showing 6291-6300 of 7021 results for "".
- New Web Tool May Curb Indoor Tanning Use Among Coedshttps://practicaldermatology.com/news/new-web-tool-may-curb-indoor-tanning-use-among-coeds/2458737/A web-based intervention that taps into indoor tanning users’ perceptions about the value of tanning may help curb tanning bed use among young females, suggests research out of Rutgers Cancer Institute of New Jersey in New Brunswick. Research has shown that some indoor tanners do so
- L'Oréal Debuts Wearable Electronic UV Monitorhttps://practicaldermatology.com/news/loral-debuts-wearable-electronic-uv-monitor/2458740/Earlier this month at the Consumer Electronics Show, L’Oréal unveiled My UV Patch, a stretchable skin sensor designed to monitor UV exposure and help consumers educate themselves about sun protection. L’Oréal Group’s dermatological skincare brand, La Roche-Posay, i
- FDA Approves Two New indications for Cosentyxhttps://practicaldermatology.com/news/fda-approves-tow-new-indications-for-cosentyx/2458745/The FDA has approved Cosentyx® (secukinumab, Novartis) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both life-long, painful and debilitating inflammatory diseases tha
- Indoor Tanning Linked to Teen Substance Abusehttps://practicaldermatology.com/news/indoor-tanning-linked-to-teen-substance-abuse/2458742/New research links teen indoor tanning with substance abuse. In a study of Colorado high school students, teens who took steroids were among the most likely to use tanning beds, especially adolescent boys. Alcohol consumption in the past 30 days, marijuana use and lifetime use of select i
- Is Pregnancy-Associated Melanoma More Lethal? Study Says Yeshttps://practicaldermatology.com/news/is-pregnancy-associated-melanoma-more-lethal-study-says-yes/2458744/Women who develop melanoma during their pregnancy or within one year of it are more likely to die from the disease, a new study suggests. Specifically, women diagnosed with malignant melanoma during their pregnancy or within one year of giving birth were 5.1-times as likely to die, 6.9-ti
- Concern About Zika Virus in US Set to Escalatehttps://practicaldermatology.com/news/concern-about-zika-virus-in-us-set-to-escalate/2458751/U.S dermatologists may start to receive calls from patients who are concerned about infection with Zika virus – particularly pregnant ones. Zika is now spreading rapidly across Latin America and the Caribbean. So far, one case has been identified in Houston, but the possibility
- Almirall Exercises Call Option to Acquire ThermiGenhttps://practicaldermatology.com/news/almirall-exercises-call-option-to-acquire-thermigen/2458755/Barcelona pharma company Almirall, S.A., is stepping up their plans to take on ThermiGen LLC. The company is now exercising their call option to acquire 100 percent of the share capital of ThermiGen.
- Ranbaxy Launches Patient Education Resources for Acne Patients Featuring Athlete Kelly Clarkhttps://practicaldermatology.com/news/ranbaxy-launches-patient-education-resources-for-acne-patients-featuring-athlete-kelly-clark/2458758/Ranbaxy Laboratories Inc, a SUN PHARMA company, has launched of a variety of patient education resources featuring gold medal-winning snowboarder and 2015 ESPY Best Female Action Sports Athlete Kelly Clark. The tools are housed on ABSORICA.COM. Absorica<
- Allergan Expands Neurotoxin Pipeline with Anterios Acquisitionhttps://practicaldermatology.com/news/allergan-expands-neurotoxin-pipelinewith-anterios-acquisition/2458763/Allergan plc has acquired Anterios, Inc., a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential devel
- Paratek To Complete Omadacycline Phase 3 Skin Trial Earlier Than Expectedhttps://practicaldermatology.com/news/paratek-completes-enrollment-for-omadacycline-phase-3-skin-trial-earlier-than-expected/2458767/Paratek Pharmaceuticals, Inc. may report top-line data from its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSS